Antigen-independent suppression of ocular angiogenesis via the Fc receptor

摘要 异常血管生成，一种新血管形成的过程，与多种疾病有关 影响世界近10%人口的疾病。在新的和令人兴奋的工作中，我们使 令人惊讶的观察到，人类IgG1作为一类，抑制了多种模型的眼球和 小鼠和细胞中的非眼部血管生成与其实际靶点无关。这个目标- 独立的血管抑制作用是通过FcγRI受体信号途径实现的。给定 血液中IgG1蛋白的丰富性及其广泛的治疗用途，我们的发现 承担更广泛的重要性，以更好地了解 抗体。Ig G/Fc受体对血管系统调控的范围和确切机制 仍有待破译。因此，明确免疫分子信号转导机制具有重要意义。 介导人IgG1FcγRI连接的血管抑制效应的途径。它是 描述治疗性FcγRI结合蛋白对细胞类型的影响也很重要 以及参与异常血管生成的分子途径。除了推进 关于免疫球蛋白/Fc介导的血管抑制的基础生物学，我们的发现也可能解决 通过改进现有的含有IgG1的药物来满足重大的眼科需求。为此，我们将 确定合理指导重新给药或重新配制贝伐单抗，全长 人源化的IgG1抗体，通过利用这一点，可以显著提高其治疗效果 新发现的抗血管生成活性，这与VEGFA中和作用是分开的。按顺序 为了实现这些目标，我们建议在更好地模拟模型中进行详细的研究 人类的血管和免疫系统。我们将使用鼠标(包括人性化)模型 角膜和脉络膜新生血管的研究提供新的功能和分子见解 了解γ/Fc Ig G 1/Fc RI信号如何参与调节血管生成。由此得出的结论 该项目将帮助阐明血管系统的创新分子基础，可以针对 由血管异常生长引起的多种眼部病变。因此，这项建议是 与NEI愿景的视网膜疾病和免疫学项目的双重目标保持一致 研究：需求、差距和机遇战略计划。

Abstract Aberrant angiogenesis, a process of new blood vessel formation, is implicated in a variety of diseases that affect nearly 10% of the world’s population. In new and exciting work, we made the surprising observation that human IgG1, as a class, suppresses multiple models of ocular and non-ocular angiogenesis in mice and cells independent of their actual target. This target- independent angiostatic effect is mediated through FcγRI receptor signaling. Given the abundance of IgG1 proteins in the blood, as well as their widespread therapeutic use, our findings assume broad importance in better understanding the full range of the biological effects of antibodies. The extent and precise mechanisms of IgG/Fc receptor modulation of the vasculature remain to be deciphered. Therefore, it is critical to define the immunological molecular signaling pathways responsible for mediating the angioinhibitory effects of human IgG1/FcγRI ligation. It is also important to delineate the influence of therapeutic FcγRI-binding proteins on the cell types and molecular pathways involved in aberrant angiogenesis. In addition to advancing the fundamental biology of IgG/Fc-mediated angiosuppression, our findings may also address a significant ophthalmic need by improving existing IgG1-containing medicines. To that end, we will determine whether a rationally guided re-dosing or reformulation of bevacizumab, a full-length humanized IgG1 antibody, can substantially improve its therapeutic efficacy by exploiting this newly discovered anti-angiogenic activity, which is separate from VEGFA neutralization. In order to accomplish these goals, we propose to perform detailed studies in models that better mimic the human vascular and immune systems. We will utilize mouse (including humanized) models of corneal and choroidal neovascularization to provide novel functional and molecular insights into how IgG1/FcγRI signaling contributes to modulation of angiogenesis. Findings from this project will help illuminate innovative molecular basis of the vasculature that can be targeted in the multitude of ocular pathologies caused by abnormal vessel growth. As such, this proposal is aligned with the dual goals of the Retinal Diseases and Immunology Programs of NEI's Vision Research: Needs, Gaps, and Opportunities Strategic Plan.